The US accounts for 45% of global pharmaceutical sales. Even if they're limited to "only" half of the global pharmaceutical market, that doesn't sound like the worst position to be in.
"sooner rather than later" won't be in 4 and could take 8! years (that's seems later to me)
If you're concerned about their longevity it looks like they'll have plenty of cash to figure it out over plenty of time.
I hate how this world works :/
The fact that there are 5 middle men is... more of a moat in this case? They've solved a complex, intractable problem profitably. Does this mean they're a 20-year company? Eh, not without some significant additional revenue streams or pivots into different areas, and to that point I agree with you about their vulnerability. But for the next 10 years? These are good margins building a business that only incrementally reduces the fucking over of the consumer.
“Medicare for All”, and while it's not part of the current platform (which focussed on a public option), removing federal program barriers to states enacting universal plans while participating in the various federal plans is part of the platform, and state policies providing models for federal progress is a common thing.
But, more immediately, even without Medicare for All, the Democratic 2020 has a plan for universality centered around a public zero-deductible option that all Americans would be able to buy into via existing exchanges and with existing exchange subsidies and some low income Americana would be enrolled in automatically with no premiums.
You can keep waiting for a government solution. In the meantime I will continue to be a happy customer of GoodRx.